FORM PTO-1449 (REV. 7-85) U.S. DEPAR MENT OF COMMERCE PATENT AND TRADEMARK OFFICE

CE ATTY. DC ATTY. DC

APPLICATION NO. 09/891,750 APPLICANT MORIARTY ET AL. FILING DATE

JUNE 26, 2001

Sheet 1 of 2

Group 1624

(Use several sheets if necessary)

SEP 28 2001 SEP
CATENTA TRACCIO

INFORMATION DISCLOSURE CITATION

U.S. PAT	ENT	DOCL	JMENTS
----------	-----	------	--------

		TA TO SE					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
M	AA	5,840,893	11/24/98	Bukrinsky et al.	544	329	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	АН						
	Al						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
10/5	AM	EP834,507	4/8/98	Europe				
_V/\^	AN	EP969004	1/5/00	Europe				
V.5	AO	WO95/30642	11/16/95	PCT				
W	AP	WO98/24782	6/11/98	PCT				
<i>V</i>	AQ	WO99/01442	1/14/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

\mathcal{M}	AR	Fujiwara et al., Bioorganic & Medicinal Chemistry Letters, Vol. 10, p. 1317 - 1320 (2000)
V	AS	Raingeaud et al., Molecular And Cellular Biology, Vol. 16, No. 3, p. 1247 - 1255 (March 1996)
V)	АТ	Henry et al., Drugs and the Future, Vol. 24 (12), p. 1345 - 1354 (1999)
EXAMIN	ER \	1. Baleise barrer DATE CONSIDERED 6/12/02

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DO TET NO

Sheet 2 of 2

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

QA0239ACIP APPLICATION NO. 09/891,750 APPLICANT MORIARTY ET AL. FILING DATE JUNE 26, 2001

Group 1624

THER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) *** Company of the Co AA Vn Moreland et al., Annals of Internal Medicine, Vol. 130, No. 6, p. 478 - 486 (March 1999) AΒ Bundgaard, Advanced Drug Delivery Reviews, Vol. 3, p. 39 - 65 (1989) AC Sabituro et al., Current Medicinal Chemistry, Vol. 6, p. 807 - 823 (1999) AD Rankin et al., British Journal of Rheumatology, Vol. 34, p. 334 - 342 (1995) ΑE Kotlyarov et al., Nature Cell Biology, Vol. 1, p. 94- 97 (1999) AF Bodor et al., Annual Reports In Medicinal Chemistry, Vol. 22, p. 303 - 313 (1987) AG ΑH ΑI ΑJ AK ALAM AN **EXAMINER** DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.